Optional product analytics
With your permission, we use privacy-limited analytics to understand which research journeys work. We do not run advertising trackers or session replay. You can change this choice in Preferences. Read the Privacy Policy.
Intuitive Surgical Inc.'s published Sell conclusion compares the analysis-date price with fair value and potential value. Read the full report for assumptions, evidence, and material risks.
| Market cap | $143.1B | |
|---|---|---|
| Revenue (ttm) | 11.6B | |
| Net income (ttm) | 3B | |
| EPS (ttm) | $8.27 | |
| Shares out | 346.6M | |
| P/E (trailing) | 53.6x | |
| P/E (forward) | 33.3x | |
| Volume | 1,193,065 | |
| Beta | 1.46 |
Recent price action with selectable time range.
| Item | P1 | P2 | P3 | P4 | P5 | Trend |
|---|---|---|---|---|---|---|
| Period | 2021-12-31 | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2025-12-31 | Trend |
| Revenue | $5.71B | $6.22B | $7.12B | $8.35B | $10.06B | +15.2% |
| Gross profit | $3.96B | $4.20B | $4.73B | $5.63B | $6.64B | +13.8% |
| Operating income | $1.82B | $1.58B | $1.77B | $2.35B | $2.95B | +12.8% |
| Net income | $1.70B | $1.32B | $1.80B | $2.32B | $2.86B | +13.8% |
| EPS (diluted) | $4.66 | $3.65 | $5.03 | $6.42 | $7.87 | +14.0% |
| EBITDA | $2.13B | $1.97B | $2.36B | $3.14B | $3.99B | +17.0% |
| R&D | $671.0M | $879.0M | $998.8M | $1.15B | $1.31B | +18.2% |
| SG&A | $1.47B | $1.74B | $1.96B | $2.14B | $2.39B | +12.9% |
Recent company headlines from major financial publishers.
In the Base scenario, representing the modal fundamental trajectory, Intuitive sustains steady procedural compounding consistent with corporate guidance. System placements in mature domestic markets tilt heavily toward trade-in upgrades rather than greenfield additions, while international expansion through tiered offerings partially balances public healthcare reimbursement delays. Normalized cash flows and cost of equity discounting yield a Base scenario target of $195.88 with a probability of 60.0% and an expected return of -51.7% against $405.18, aligning closely with the house Fair value of $195.88. This path would be disconfirmed by a sudden procedural volume contraction below double digits or by rapid multiple compression toward medtech peer medians.
In the Bull scenario, accelerated da Vinci replacement cycles across domestic hospitals and rapid uptake in outpatient ambulatory surgical centers, combined with faster procedural penetration in underpenetrated international markets via the value-tier platform, drive procedural expansion above guided ranges. Under this trajectory, fundamental earnings power supports a scenario target of $235.14 with an estimated scenario probability of 20.0% and an expected return of -42.0% relative to $405.18. This outcome requires uninterrupted hospital capital budgets, seamless digital ecosystem software monetization, and prompt resolution of overseas tender backlogs. The scenario would be disconfirmed if hospital capital freezes or if pricing pressure in Asian accounts dampens international placement velocity.
| Ke ↓ / g → | 2.5% | 2.8% | 3.0% | 3.3% | 3.5% |
|---|---|---|---|---|---|
| 9.2% | $205 | $206 | $207 | $209 | $211 |
| 9.7% | $199 | $200 | $201 | $203 | $204 |
| 10.2% | $194 | $195 | $196 | $197 | $198 |
| 10.7% | $189 | $190 | $191 | $192 | $193 |
| 11.2% | $185 | $186 | $187 | $187 | $188 |
Upcoming earnings date and setup when available.
The rating each month's published research edition carried. A rating compares the price at analysis with the Fair value; it is not a record of whether the call was right.
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 |
